SAG

• Description :

  SAG is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM) . SAG activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Smo

• Type :

  Reference compound

• Related Pathways :

  Stem Cell/Wnt

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/SAG.html

• Concentration :

  10mM

• Purity :

  99.79

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=C(Cl)C2=CC=CC=C2S1)N([C@H]3CC[C@H](NC)CC3)CC4=CC=CC(C5=CC=NC=C5)=C4

• Molecular Formula :

  C28H28ClN3OS

• Molecular Weight :

  490.06

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Chen JK, et al. Small molecule modulation of Smoothened activity. Proc Natl Acad Sci U S A. 2002 Oct 29;99 (22) :14071-6.|[2]Stanton BZ, et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol. 2009 Mar;5 (3) :154-6.|[3]Lee S, et al. Combining Smoothened Agonist (SAG) and NEL-like protein-1 (NELL-1) Enhances Bone Healing. Plast Reconstr Surg. 2017 Feb 13|[4]Fish EW, et al. Preaxial polydactyly following early gestational exposure to the smoothened agonist, SAG, in C57BL/6J mice. Birth Defects Res A Clin Mol Teratol. 2016 Nov 1|[5]Guerrini G, et, al. Inhibition of smoothened in breast cancer cells reduces CAXII expression and cell migration. J Cell Physiol. 2018 Dec; 233 (12) : 9799-9811.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Citation 01 :

  Adv Sci (Weinh) . 2025 Jan 9:e2411675.|Biochem Pharmacol. 2021 Aug:190:114593.|Biomedicines. 2022 Apr 18;10 (4) :928. |bioRxiv. 2025 July 21.|bioRxiv. 2025 March 25.|Cell Commun Signal. 2024 Feb 15;22 (1) :123.|Cell Rep Methods. 2024 May 8:100777.|Cell Rep. 2020 Apr.|Cell Res. 2022 Mar;32 (3) :288-301.|Cell Stem Cell. 2025 Jul 3;32 (7) :1071-1086.e8.|Development. 2018 Sep 20;145 (18) . pii: dev164830.|Ecotoxicol Environ Saf. 2025 Aug 6:303:118813.|Exp Eye Res. 2025 May 21:110440.|Glia. 2021 Jul;69 (7) :1782-1798.|iScience. 2022 Dec 26;26 (1) :105898.|iScience. 2024 Feb 5;27 (3) :109111.|J Biomed Mater Res A. 2025 Oct;113 (10) :e38001.|J Cell Mol Med. 2022 Jun;26 (11) :3213-3222.|J Pathol. 2025 Nov 6.|J Pharm Biomed Anal. 2017 Aug 5:142:201-209.|J Tradit Complement Med. 2025 Jun 14.|Mol Brain. 2021 Jul 19;14 (1) :116.|Molecules. 2017 Dec 31;23 (1) . pii: E85.|Patent. US20240247230A1.|Research Square Preprint. 2021 Sep.|Sci Adv. 2023 Jun 16;9 (24) :eadf6927.|Tissue Cell. 2024 Nov 28:92:102643.|Toxins. 2021 Aug 22;13 (8) :585.|University of Bonn. 2021 May 21.|Cancer Sci. 2021 Oct;112 (10) :4176-4186.|Drug Dev Res. 2019 Nov;80 (7) :992-999.|Sci Adv. 2025 Jan 10;11 (2) :eads5434.|Sci Rep. 2025 Oct 14;15 (1) :35928.|Nat Commun. 2024 Feb 2;15 (1) :987.|UNIVERSIDAD DE CONCEPCIÓN. 2023 Apr.

• CAS Number :

  [912545-86-9]